Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Debt (2019 - 2025)

BridgeBio Pharma's Non-Current Debt history spans 7 years, with the latest figure at $564.6 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 3.56% year-over-year to $564.6 million; the TTM value through Dec 2025 reached $564.6 million, up 3.56%, while the annual FY2025 figure was $564.6 million, 3.56% up from the prior year.
  • Non-Current Debt for Q4 2025 was $564.6 million at BridgeBio Pharma, up from $545.2 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $564.6 million in Q4 2025 and bottomed at $90.8 million in Q1 2021.
  • The 5-year median for Non-Current Debt is $434.7 million (2024), against an average of $389.1 million.
  • The largest annual shift saw Non-Current Debt fell 1.79% in 2021 before it soared 378.3% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $430.8 million in 2021, then increased by 0.06% to $431.0 million in 2022, then increased by 3.59% to $446.4 million in 2023, then increased by 22.11% to $545.2 million in 2024, then increased by 3.56% to $564.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Non-Current Debt are $564.6 million (Q4 2025), $545.2 million (Q4 2024), and $436.2 million (Q3 2024).